NECLIFEPharmaceuticals
Nectar Lifesciences Ltd — Profit & Loss Statement
₹9.30
-7.74%
Nectar Lifesciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Expenses | 1.76K Cr | 1.59K Cr | 1.53K Cr | 1.57K Cr | — |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 12.15 Cr | 2.49 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.30 | 0.30 | 0.27 | — |
| Normalized EBITDA | -24.57 Cr | 166.13 Cr | 58.98 Cr | 151.58 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -113.68 Cr | 4.99 Cr | -24.18 Cr | 25.05 Cr | — |
| Reconciled Depreciation | 62.39 Cr | 60.72 Cr | 59.12 Cr | 56.97 Cr | — |
| Reconciled Cost Of Revenue | 1.37K Cr | 1.20K Cr | 1.33K Cr | 1.37K Cr | — |
| EBITDA | -24.57 Cr | 166.13 Cr | 99.50 Cr | 160.99 Cr | — |
| EBIT | -86.96 Cr | 105.41 Cr | 40.38 Cr | 104.02 Cr | — |
| Net Interest Income | -74.58 Cr | -87.14 Cr | -77.76 Cr | -76.93 Cr | — |
| Interest Expense | 74.58 Cr | 87.14 Cr | 82.80 Cr | 69.94 Cr | — |
| Normalized Income | -113.68 Cr | 4.99 Cr | -52.54 Cr | 18.13 Cr | — |
| Net Income From Continuing And Discontinued Operation | -113.68 Cr | 4.99 Cr | -24.18 Cr | 25.05 Cr | — |
| Diluted Average Shares | 22.42 Cr | 22.70 Cr | 22.43 Cr | 22.43 Cr | — |
| Basic Average Shares | 22.42 Cr | 22.70 Cr | 22.43 Cr | 22.43 Cr | — |
| Diluted EPS | -5.07 | 0.22 | -1.08 | 1.12 | — |
| Basic EPS | -5.07 | 0.22 | -1.08 | 1.12 | — |
| Diluted NI Availto Com Stockholders | -113.68 Cr | 4.99 Cr | -24.18 Cr | 25.05 Cr | — |
| Net Income Common Stockholders | -113.68 Cr | 4.99 Cr | -24.18 Cr | 25.05 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -113.68 Cr | 4.99 Cr | -24.18 Cr | 25.05 Cr | — |
| Net Income Including Noncontrolling Interests | -113.68 Cr | 4.99 Cr | -24.18 Cr | 25.05 Cr | — |
| Net Income Continuous Operations | -113.68 Cr | 4.99 Cr | -24.18 Cr | 25.05 Cr | — |
| Tax Provision | -47.85 Cr | 13.27 Cr | -18.24 Cr | 9.03 Cr | — |
| Pretax Income | -161.53 Cr | 18.27 Cr | -42.42 Cr | 34.08 Cr | — |
| Other Non Operating Income Expenses | 1.89 Cr | 13.03 Cr | 42.24 Cr | 11.29 Cr | — |
| Net Non Operating Interest Income Expense | -74.58 Cr | -87.14 Cr | -77.76 Cr | -76.93 Cr | — |
| Interest Expense Non Operating | 74.58 Cr | 87.14 Cr | 82.80 Cr | 69.94 Cr | — |
| Operating Income | -88.85 Cr | 92.38 Cr | -5.17 Cr | 101.60 Cr | — |
| Operating Expense | 390.81 Cr | 389.46 Cr | 197.42 Cr | 197.73 Cr | — |
| Other Operating Expenses | 235.05 Cr | 245.62 Cr | 2.49 Cr | 2.66 Cr | — |
| Depreciation And Amortization In Income Statement | 62.39 Cr | 60.72 Cr | 59.12 Cr | 56.97 Cr | — |
| Depreciation Income Statement | 62.39 Cr | 60.72 Cr | 50.11 Cr | 56.97 Cr | — |
| Gross Profit | 301.96 Cr | 481.84 Cr | 192.24 Cr | 299.33 Cr | — |
| Cost Of Revenue | 1.37K Cr | 1.20K Cr | 1.33K Cr | 1.37K Cr | — |
| Total Revenue | 1.67K Cr | 1.68K Cr | 1.52K Cr | 1.67K Cr | — |
| Operating Revenue | 1.67K Cr | 1.68K Cr | 1.52K Cr | 1.67K Cr | — |
| Total Unusual Items | — | 0.64 Cr | 40.51 Cr | 9.41 Cr | -37.43 Cr |
| Total Unusual Items Excluding Goodwill | — | 0.64 Cr | 40.51 Cr | 9.41 Cr | -37.43 Cr |
| Interest Income | — | 12.39 Cr | 1.73 Cr | 1.88 Cr | 2.68 Cr |
| Rent Expense Supplemental | — | 1.89 Cr | 1.83 Cr | 1.76 Cr | 1.78 Cr |
| Special Income Charges | — | 0.46 Cr | 40.41 Cr | 9.41 Cr | -37.47 Cr |
| Other Special Charges | — | -0.46 Cr | -40.41 Cr | -9.41 Cr | 25.45 Cr |
| Total Other Finance Cost | — | -2.48 Cr | -3.31 Cr | 8.87 Cr | 26.27 Cr |
| Interest Income Non Operating | — | 12.39 Cr | 1.73 Cr | 1.88 Cr | 2.68 Cr |
| Amortization | — | 11.29 Cr | 9.01 Cr | — | — |
| Selling General And Administration | — | 56.18 Cr | 57.15 Cr | 61.82 Cr | 66.18 Cr |
| Selling And Marketing Expense | — | 38.99 Cr | 42.87 Cr | 48.03 Cr | 50.82 Cr |
| General And Administrative Expense | — | 17.19 Cr | 14.28 Cr | 13.79 Cr | 15.36 Cr |
| Rent And Landing Fees | — | 1.89 Cr | 1.83 Cr | 1.76 Cr | 1.78 Cr |
| Write Off | — | — | — | 0.00 | 12.02 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Nectar Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.